Thomas P. Kole, M.D., Ph.D
210 posts

Thomas P. Kole, M.D., Ph.D
@drthomaskole
Radiation Oncologist at Memorial Sloan Kettering Cancer Center (MSK). The comments I am expressing are my own and do not represent the views or opinions of MSK





BREAKING: AI can now analyze stocks like Wall Street analysts (for free). Here are 10 insane Claude prompts that replace $2,000/month Bloomberg terminals (Save for later)



@DrSpratticus This is an AI-generated visual abstract. It was not published in the journal. It did its job because it captured attention in a viral way (so viral that it seems to have touched a nerve in a certain crowd…). Read the article.



Why do we do math in school? When I asked this question as a kid, my teachers always told me, “You’ll use it one day.” That’s almost always false. Most adults are never going to be in a sticky situation with two binomials, thinking, thank goodness I can FOIL my way out of this mess. Most of us get by just fine without ever solving for x again. And especially in an AI age, fewer and fewer people will “use math” in the narrow, practical sense. But the origins of math have never been primarily about utility. Math is formative. It trains the mind to love what is true, to recognize what is orderly, and to be drawn toward what is beautiful. It teaches us that the universe is not chaos, but something intelligible, something structured, something that can be known. And you can see that truth made visible in the world’s most breathtaking churches and cathedrals: arches, vaults, domes, proportions, symmetry, harmony, light—geometry turned into glory. The mathematics that shapes a cathedral is not cold or sterile. It’s the language of wonder, carved into stone. We don’t teach math because everyone will use it. We teach math because it forms the kind of person who can see that reality has meaning.





A multi-institutional cohort study found that breast cancer patients with TP53 pathogenic variants who underwent radiation therapy faced a significantly elevated risk (8.8%) of developing in-field sarcoma at 15 years compared to the general population. ja.ma/494i44f



📢We are overjoyed to announce that Dr @HimanshuNagarMD will be joining @MSKCancerCenter this summer as our Genitourinary Cancer Disease site leader. Dr Nagar is a compassionate clinician & innovative researcher. We are excited to see where he leads our GU #radonc team!





Provocative study of radical prostatectomy without prior biopsy for patients w/ PSA>10 + high suspicion MRI/PSMA PET. All patients had clinically significant #prostatecancer on final pathology. No data yet if avoiding biopsy impacts functional outcomes -Stief #aaeu23








